Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

RNAi

This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Gaining NICE recommendation would be a major milestone for both companies – Onpattro is Alnylam’s debut product from its RNA interference (RNAi) drug platform, while Tegsedi is similarly Akcea’s first

Latest news

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    Bolsters pipeline ahead of Soliris patent protection loss. Alexion has signed a deal with RNAi specialists Dicerna to discover therapies for complement-mediated diseases. ... In return, Alexion will have access to Dicerna’s GalXC technology, which is

  • Alnylam seeks fast-track filing with biomarker data Alnylam seeks fast-track filing with biomarker data

    Early filing reflects FDA desire for faster approvals. Alnylam is set to file its next RNAi drug candidate givosiran with regulators after producing strong phase 3 data. ... After 15 years building its RNAi ‘gene silencing’ platform, the Cambridge,

  • Alnylam claims RNAi milestone with Onpattro approval Alnylam claims RNAi milestone with Onpattro approval

    After years of ups and downs, triumph for gene-silencing tech. Alnylam’s faith in the gene-silencing potential of RNA interference (RNAi) drugs has finally paid off, with the US ... RNAi drugs are used to block gene expression, binding to the messenger

  • The year of the blockbuster The year of the blockbuster

    UK,   the projected blockbuster list includes four biologicals, one  RNAi-based drug, one vaccine  and six small molecules. ... It is expected to become the first FDA-approved RNAi therapeutic following Alnylam’s completion of its new drug

  • Optimum wins Silence Therapeutics account Optimum wins Silence Therapeutics account

    The healthcare communications group will advise in financial PR. London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.

More from news
Approximately 7 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences” genes, ... Its RNAi technology can be used to target any gene expressed in

  • Boosting pharma’s metabolic rate Boosting pharma’s metabolic rate

    New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.

  • Deal Watch September 2016 Deal Watch September 2016

    800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's

  • Pharma deals during January 2014 Pharma deals during January 2014

    The deal comprised a range of RNAi assets including pre-clinical candidates, IP and delivery technologies. ... The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Bruce Peacock joins Dicerna from Ophthotech Bruce Peacock joins Dicerna from Ophthotech

    Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Quick links

Infographics

Multimedia